In several mouse models of MYC-driven cancers, tumor regression by MYC suppression was hampered by the concomitant repression of TP53 or RB1 proteins, which highlighted the relevance of intact TP53 and RB1 pathways for the treatment of cancer by MYC targeting [11–13]. This evidence concerns the gene MYC and neoplasm.